By looking at the pipeline and its progression. I am looking longer term. As the pipeline expands with new trials, the investment derisks a bit, as we have more kicks at goal.
But CHM is still a high-risk investment at the moment. For me, the low SOI and low market cap for novel pipeline make this an accumulate, and these prices offset some risk.
We are starting the final cohort of the phase 1 GBM trial. We are waiting for data from the 3rd cohort.
NK tech has also started dosing in a combo trial.
More of the pipeline is heading to the clinic this year.
CHM has a very novel, diverse, and cutting-edge new tech pipeline. It's all addressing cancers with unmet needs. The team are from companies that introduced car t to the world. They are experienced in drug development.
5 bags from where we are now would be low fair value for our two trials as of now in a market two years ago.
So high risk with lots of up side potential. But probably not a place for a nervous investor.
CHM Price at posting:
6.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)